Abstract 963P
Background
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. Early detection of HCC is critical for timely treatment and a better prognosis. In this prospective study (ASCEND-Hep, NCT04835675), we aimed to explore multi-omics including cell-free DNA (cfDNA) methylation, mutation, and α-fetoprotein (AFP) in early detection of HCC.
Methods
This multicenter study prospectively collected blood samples from patients with HCC and benign liver diseases. Age-matched non-cancer controls were obtained from a previous study. Methylation and mutation were detected through a methylation panel of 161,984 CpG sites and a cancer-associated 168-gene panel, respectively. Models were developed in a training set (cancer: 172; non-cancer: 206) and tested in a validation set (cancer: 117; non-cancer: 140). Then the locked models were validated in an independent validation set (cancer: 158; non-cancer: 637).
Results
In the training set, cfDNA methylation model had a higher area under curve than AFP and mutation alone (P<0.05). In the validation set, the methylation model yielded an overall sensitivity of 92.3% (95% CI, 85.9%–96.4%) at a specificity of 95.0% (90.0%–98.0%). Meanwhile, AFP >400 ng/mL had a sensitivity of 27.3% (18.8%–37.2%) with a specificity of 100.0% (96.5%–100.0%). Combining cfDNA methylation and AFP showed a better performance with a sensitivity of 94.0% (88.1%–97.6%) and a specificity of 95.0% (90.0%–98.0%), while the addition of mutation did not further improve the performance. Consistent results were observed in the independent validation set that the combined model achieved a sensitivity of 90.5% (84.8%–94.6%) at a specificity of 97.3% (95.8%–98.4%). The sensitivity of the combined model in Barcelona Clinic Liver Cancer Classification 0–A was 87.1% (78.0%–93.4%).
Conclusions
cfDNA methylation yielded superior performance than AFP and mutation alone. Our study highlights a potential clinical utility of combining cfDNA methylation and AFP for HCC early detection.
Clinical trial identification
NCT04835675.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Burning Rock Bioengineering Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18